Tailored chemo doses may help older pancreatic cancer patients maintain independence
NCT ID NCT02143219
First seen Apr 25, 2026 · Last updated May 10, 2026 · Updated 2 times
Summary
This study tested a personalized dosing approach for the chemotherapy combination FOLFIRINOX in 72 patients aged 70 and older with metastatic pancreatic cancer. The goal was to see if adjusting doses based on genetic markers could reduce severe side effects while still controlling the cancer. The approach aims to help older patients maintain their ability to perform daily activities during treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TOXICITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CH Vendée
La Roche-sur-Yon, 85925, France
-
Centre Eugène marquis
Rennes, 35042, France
-
Centre Oscar Lambret
Lille, 59020, France
-
ICM (Val d'Aurelle)
Montpellier, 34298, France
-
ICO Paul Papin
Angers, 49000, France
-
ICO René Gauducheau
Saint-Herblain, 44805, France
Conditions
Explore the condition pages connected to this study.